Publication from Taylor & Francis Online: In recent years, the development of bispecific antibody (bsAb) has become a major trend in the biopharmaceutical industry. By simultaneously engaging 2 molcular targets, bsAbs show unique mechanisms of action that could lead to clinical benefits unattainable by conventional monoclonal antibodies.
First FIT-Ig® Cancer Therapy Expected to Enter the Clinic in 2018 Shanghai, China, May 31, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and WuXi Biologics, a WuXi AppTec Affiliate, announced today a collaboration to advance EpimAb’s first candidate, EMB-01, towards IND-filing. EMB-01 is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. Under the agreement, WuXi will be responsible for establishing the chemistry, manufacturing and […]
Shanghai, China, April 25, 2017 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today the completion of a $25 million Series A financing round. The financing was led by Oriza Seed Capital and included investments from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group. With the funding, Epimab will advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in immuno-oncology and other areas with a high unmet medical need. […]
Cambridge/UK and Shanghai/China, October 11, 2016 – Kymab, a leading human monoclonal antibody biopharmaceutical company, and EpimAb Biotherapeutics, an emerging biopharmaceutical company specializing in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse® platform. Kymab will have the development and commercialization rights […]
Shanghai/Suzhou, June 6th, 2016 – EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Innovent Biologics, one of the leading biopharmaceutical companies in China, today announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China. In return for commercialization […]